PSMD1 and COVID-19: Indeed, while cross-neutralizing antibodies targeting S2 have been identified in SARS-CoV-2-positive and -negative patient sera29–31, these have not been shown yet to prevent or treat COVID-19 in contrast to S1-specific monoclonal treatments32,33.